%0 Journal Article
%A Telli, Tugce
%A Lopes, Leonor
%A Karpinski, Madeleine
%A Pabst, Kim M
%A Grünwald, Viktor
%A Shi, Kuangyu
%A Hadaschik, Boris
%A Kesch, Claudia
%A Umutlu, Lale
%A Herrmann, Ken
%A Seifert, Robert
%A Fendler, Wolfgang P
%T Prognostic value of [18F]FDG- and PSMA-PET in patients evaluated for [177Lu]Lu-PSMA therapy of mCRPC.
%J European journal of nuclear medicine and molecular imaging
%V 52
%@ 1619-7070
%C Heidelberg [u.a.]
%I Springer-Verl.
%M DKFZ-2025-00601
%P 3199–3210
%D 2025
%Z Volume 52, pages 3199–3210, (2025) 
%X To improve [177Lu]Lu-Prostate-specific membrane antigen therapy (LuPSMA) selection, this study investigates the prognostic value of PSMA and 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG)-PET in metastatic castration-resistant prostate cancer (mCRPC) patients considered for LuPSMA therapy.We conducted a retrospective analysis in 152 mCRPC patients referred for LuPSMA therapy who underwent PSMA and [18F]FDG-PET/CT. Of these, 104 patients (68.4
%K Biomarkers (Other)
%K FDG (Other)
%K PSMA (Other)
%K Prognostics (Other)
%K Prostate cancer (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40113645
%R 10.1007/s00259-025-07198-y
%U https://inrepo02.dkfz.de/record/300101